Forest Laboratories has announced it will discontinue sale of NAMENDA tablets on August 15. The company will continue to sell the oral solution of NAMENDA and once-daily extended release capsules.
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company, today announced that it intends to continue to market both its NAMENDA® ...
MUMBAI, India--(BUSINESS WIRE)--Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its ...
Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) N-methyl ...
In nearly 20 years, aside from cholinesterase inhibitors, memantine is the only drug approved for the treatment of Alzheimer's disease (AD). Memantine is an uncompetitive N-methyl-D-aspartate receptor ...
The latest clinical practice guideline from the Deprescribing Guidelines for the Elderly Project, based at the Bruyère Research Institute, Ottawa, Canada, focuses on the discontinuation of ...
The dementia drug memantine showed promise for improving social functioning in a small trial of youth with autism. Nine of 16 children and adolescents treated with memantine met the response criteria ...
Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda ® Tablets. Mylan received final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback